IGF1R and neoplasm: Unfortunately, IGF1R inhibition using monoclonal antibodies (e.g. cixutumumab, dalotuzumab and robatumumab) or tyrosine kinase inhibitors (linsitinib) has not succeeded in inducing durable remissions in bone sarcomas or other tumour types so far [10].